Pictured: Front view of the CDC museum in Georgia/iStock, hapabapa

图为佐治亚州疾病预防控制中心博物馆正面图

The U.S. Centers for Disease Control and Prevention on Wednesday updated its respiratory syncytial virus vaccine guidelines, which now recommend the shots in all seniors aged 75 and older and in those 60 to 74 years of age who are at risk of severe disease.

。

The new recommendations apply to older adults who were not immunized last year, according to the CDC. The revised guidance replaces prior standards that endorsed the respiratory syncytial virus (RSV) vaccines for all adults aged 60 and older, which were primarily meant to “simplify … decision-making” for doctors and their patients..

据疾病预防控制中心称，新建议适用于去年未接种疫苗的老年人。修订后的指南取代了先前认可针对所有60岁及以上成年人的呼吸道合胞病毒（RSV）疫苗的标准，这些疫苗主要是为了“简化医生及其患者的……决策”。。

Following the initial roll-out of immunization last year—and the first-ever real-world data from the vaccine-eligible population—the CDC changed its vaccination guidelines to more closely reflect the burden of RSV in people 60 years and above and the cost-effectiveness of the vaccines.

继去年首次推出免疫接种以及来自疫苗合格人群的首次真实数据之后，CDC改变了其疫苗接种指南，以更密切地反映60岁及以上人群的RSV负担以及疫苗的成本效益。

CDC Director Mandy Cohen in a statement said that the revised recommendations are meant to “prioritize those at highest risk for serious illness from RSV.”

疾病预防控制中心主任曼迪·科恩（MandyCohen）在一份声明中表示，修订后的建议旨在“优先考虑呼吸道合胞病毒（RSV）感染重病风险最高的人群。”

The CDC’s Advisory Committee on Immunization Practices on Wednesday also deferred the vote on whether it would endorse the use of RSV vaccines in younger seniors aged 50 to 59 years, which RSV frontrunner GSK was hoping to target.

疾病预防控制中心的免疫实践咨询委员会周三也推迟了投票，决定是否批准在50至59岁的年轻老年人中使用RSV疫苗，RSV领跑者葛兰素史克（GSK）希望以此为目标。

The pharma’s vaccine Arexvy became the industry’s first FDA-approved RSV shot in May 2023, beating its main competitor—Pfizer’s Abrysvo—by a month. This head start proved enough time for GSK to capture most of the market, with its CEO Emma Walmsley announcing in December 2023 that Arexvy was on track to make more than £1 billion in sales in its first commercial year..

该制药公司的疫苗Arexvy于2023年5月成为业界首个FDA批准的RSV疫苗，击败了其主要竞争对手辉瑞公司的Abrysvo一个月。这一领先地位证明，葛兰素史克有足够的时间占领大部分市场，其首席执行官艾玛·沃尔姆斯利（EmmaWalmsley）于2023年12月宣布，阿雷克维（Arexvy）有望在其第一个商业年度实现超过10亿英镑的销售额。。

GSK reported in November 2023 that Arexvy captured around two-thirds of the market in its first full commercial quarter, bringing in nearly $859 million in sales. By comparison, Abrysvo generated $375 million in its first quarter. The same month, Pfizer CFO David Denton admitted in a conference that the pharma was “disappointed” by Abrysvo’s performance, as reported by Reuters..

葛兰素史克（GSK）在2023年11月的报告中称，阿雷克西（Arexvy）在其第一个完整商业季度占据了约三分之二的市场份额，实现了近8.59亿美元的销售额。相比之下，Abrysvo在第一季度创造了3.75亿美元的收入。同月，辉瑞首席财务官大卫·丹顿（DavidDenton）在一次会议上承认，据路透社报道，该制药公司对Abrysvo的表现“感到失望”。。

To secure more patients and sales, Pfizer has pushed for a pediatric indication for Abrysvo. The FDA granted it approval in August 2023, allowing pregnant mothers to get immunized with the vaccine at 32 to 36 weeks of gestation. Meanwhile, GSK’s strategy for expansion has been to broaden Arexvy’s adult population.

为了确保更多患者和销售，辉瑞公司推出了Abrysvo的儿科适应症。FDA于2023年8月批准，允许孕妇在妊娠32至36周时接种疫苗。与此同时，葛兰素史克的扩张战略是扩大阿雷克西的成年人口。

Earlier this month, the regulator allowed the use of Arexvy in adults aged 50 to 59 years..

本月早些时候，监管机构允许50至59岁的成年人使用Arexvy。。

Trailing GSK and Pfizer is Moderna, which is developing an mRNA-based RSV vaccine called mRESVIA. On Wednesday, the biotech announced that the vaccine candidate had a 50% efficacy at preventing RSV infection after 18 months, putting it well below Abrysvo and Arexvy, according to Reuters.

。据路透社报道，周三，生物技术公司宣布，候选疫苗在18个月后预防RSV感染的效果为50%，远低于Abrysvo和Arexvy。

Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

特里斯坦·马纳拉克（TristanManalac）是一位独立的科学作家，总部位于菲律宾马尼拉。在LinkedIn上与他联系，或发电子邮件至tristan@tristanmanalac.com或tristan.manalac@biospace.com.